Literature DB >> 15197487

Novel vitamin E analogue and 9-nitro-camptothecin administered as liposome aerosols decrease syngeneic mouse mammary tumor burden and inhibit metastasis.

Karla A Lawson1, Kristen Anderson, Rachel M Snyder, Marla Simmons-Menchaca, Jeffrey Atkinson, Lu-Zhe Sun, Abhik Bandyopadhyay, Vernon Knight, Brian E Gilbert, Bob G Sanders, Kimberly Kline.   

Abstract

PURPOSE: To test the anticancer properties of a nonhydrolyzable ether-linked acetic acid analogue of vitamin E, 2,5,7,8-tetramethyl-2R-(4R,8R, 12-trimethyltridecyl)chroman-6-yloxyacetic acid (alpha-TEA), and a derivative of camptothecin, 9-nitrocamptothecin (9-NC)singly and in combination against mouse mammary tumor cells (line 66 clone 4 stably transfected with green fluorescent protein; 66cl-4-GFP) cultured in vitro or transplanted subcutaneously into the inguinal region of female BALB/c mice to form established tumors.
METHODS: Following in vitro treatment of 66cl-4-GFP cells with alpha-TEA and suboptimal concentrations of 9-NC, singly or in combination, apoptosis was measured by morphological evaluation of nuclei stained with 4',6-diamidino-2-phenylindole (DAPI), and DNA synthesis arrest was measured by tritiated thymidine uptake. For in vivo analyses alpha-TEA and 9-NC, both water-insoluble compounds, were formulated into liposomes using dil-auroylphosphatidylcholine and administered by aerosol to deliver doses calculated to be 36 and 0.4 microg/mouse per day, respectively, (singly or each separately for combined treatments) 7 days per week.
RESULTS: Treatment of 66cl-4-GFP cells in culture for 3 days with a combination of alpha-TEA (10 microg/ml; singly produces 38% apoptosis), and suboptimal concentrations of 9-NC(15.6, 31.3, 62.5, or 125 ng/ml; singly produce 2-7% apoptosis), produced 47%, 58%, 64%, and 69% apoptosis. Likewise, combinations of alpha-TEA 9-NC inhibited DNA synthesis more than either agent administered singly. A significant reduction (P< 0.001)in growth of subcutaneous transplanted tumors was observed with liposome-formulated and aerosolized delivery of alpha-TEA + 9-NC to BALB/c mice. The incidence of macroscopic lung metastasis was 83% in control vs 8 % in alpha-TEA-, 9-NC-, or combination-treated mice. Fluorescence microscopic examination of lungs and axillary and brachial lymph nodes showed a statistically significant decrease in metastasis observed in alpha-TEA-,9-NC-, and combination- vs control-treated animals. Analyses of primary tumor tissue for proliferation and apoptosis showed treatment groups to have lower Ki-67 and higher terminal deoxynucleotidyl transferase-mediated nick end labeling, respectively. Treatments showed no measurable effects on two angiogenesis parameters,namely intratumoral blood volume as assessed by hemoglobin content and intratumoral blood vessel density as assessed with CD31 staining.
CONCLUSIONS: Combination treatments enhanced antiproliferative and proapoptotic activities in cell culture, and when formulated in liposomes and delivered via aerosolization to treat an aggressive and metastatic syngeneic murine mammary tumor, the combination treatment showed a significant reduction in tumor volume in comparison to either treatment alone. Mechanistically, it appears that neither enhanced apoptosis, reduced cell proliferation,nor reduced blood vessel density can fully account for the enhanced effects of the combination treatment.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15197487     DOI: 10.1007/s00280-004-0817-y

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  16 in total

Review 1.  Therapeutic liposomal dry powder inhalation aerosols for targeted lung delivery.

Authors:  Lauren Willis; Don Hayes; Heidi M Mansour
Journal:  Lung       Date:  2012-01-25       Impact factor: 2.584

Review 2.  Lymphatic drug delivery using engineered liposomes and solid lipid nanoparticles.

Authors:  Shuang Cai; Qiuhong Yang; Taryn R Bagby; M Laird Forrest
Journal:  Adv Drug Deliv Rev       Date:  2011-06-25       Impact factor: 15.470

Review 3.  Use of anti-cancer drugs, mitocans, to enhance the immune responses against tumors.

Authors:  T Hahn; M J Polanczyk; A Borodovsky; L V Ramanathapuram; E T Akporiaye; S J Ralph
Journal:  Curr Pharm Biotechnol       Date:  2013       Impact factor: 2.837

4.  Challenges associated with Penetration of Nanoparticles across Cell and Tissue Barriers: A Review of Current Status and Future Prospects.

Authors:  Sutapa Barua; Samir Mitragotri
Journal:  Nano Today       Date:  2014-04-01       Impact factor: 20.722

Review 5.  Development of regional chemotherapies: feasibility, safety and efficacy in clinical use and preclinical studies.

Authors:  Shuang Cai; Taryn R Bagby; M Laird Forrest
Journal:  Ther Deliv       Date:  2011-11

6.  Downregulation of Epidermal Growth Factor Receptor Expression Contributes to alpha-TEA's Proapoptotic Effects in Human Ovarian Cancer Cell Lines.

Authors:  Ming-Chieh Shun; Weiping Yu; Sook-Kyung Park; Bob G Sanders; Kimberly Kline
Journal:  J Oncol       Date:  2010-03-04       Impact factor: 4.375

7.  Orally active alpha-tocopheryloxyacetic acid suppresses tumor growth and multiplicity of spontaneous murine breast cancer.

Authors:  Tobias Hahn; Karen Fried; Laurence H Hurley; Emmanuel T Akporiaye
Journal:  Mol Cancer Ther       Date:  2009-06-09       Impact factor: 6.261

Review 8.  Cancer therapies utilizing the camptothecins: a review of the in vivo literature.

Authors:  Vincent J Venditto; Eric E Simanek
Journal:  Mol Pharm       Date:  2010-04-05       Impact factor: 4.939

9.  α-TEA-induced death receptor dependent apoptosis involves activation of acid sphingomyelinase and elevated ceramide-enriched cell surface membranes.

Authors:  Jing Li; Weiping Yu; Richa Tiwary; Sook-Kyung Park; Ailian Xiong; Bob G Sanders; Kimberly Kline
Journal:  Cancer Cell Int       Date:  2010-10-25       Impact factor: 5.722

10.  α-Tocopheryloxyacetic acid: a novel chemotherapeutic that stimulates the antitumor immune response.

Authors:  Tobias Hahn; Bhumasamudram Jagadish; Eugene A Mash; Kendra Garrison; Emmanuel T Akporiaye
Journal:  Breast Cancer Res       Date:  2011-01-13       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.